Evidence map›Paper›PMID 30668905›Full record

ArticleBioconjugate chemistry2019

Efficient Synthesis of Heparinoid Bioconjugates for Tailoring FGF2 Activity at the Stem Cell-Matrix Interface.

Greg W Trieger, Stephen Verespy, Philip L S M Gordts, Kamil Godula

Abstract read
In one paragraph

Article in Bioconjugate chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Heparan Sulfate Proteoglycans: Key Mediators of Stem Cell Function.Frontiers in cell and developmental biology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Greg W TriegerDepartment of Chemistry and Biochemistry , University of California San Diego , 9500 Gilman Drive , La Jolla , California 92093-0358 , United States.
Stephen VerespyDepartment of Chemistry and Biochemistry , University of California San Diego , 9500 Gilman Drive , La Jolla , California 92093-0358 , United States.
Philip L S M Gordts
Kamil GodulaDepartment of Chemistry and Biochemistry , University of California San Diego , 9500 Gilman Drive , La Jolla , California 92093-0358 , United States.ORCID 0000-0001-7953-4619
University of California San Diego · US

Funding

Transgenic & Knock-out MouseP30DK063491 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Andrea L Hevener · 2003 to 2026
$40.4M
In vivo glycan engineering at the cell-matrix interface to control stem cell fateDP2HD087954 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GODULA, KAMIL · 2015 to 2015
$2.3M
NICHD NIH HHS DP2 HD087954NIDDK NIH HHS P30 DK063491
6 · The paper itself

Abstract

Heparan sulfate glycosaminoglycans (HS GAGs) attached to proteoglycans harbor high affinity binding sites for various growth factors (GFs) and direct their organization and activity across the cell-matrix interface. Here, we describe a mild and efficient method for generating HS-protein conjugates. The two-step process utilizes a "copper-free click" coupling between differentially sulfated heparinoids primed at their reducing end with an azide handle and a bovine serum albumin protein modified with complementary cyclooctyne functionality. When adsorbed on tissue culture substrates, the glycoconjugates served as extracellular matrix proteoglycan models with the ability to sequester FGF2 and influence mesenchymal stem cell proliferation based on the structure of their HS GAG component.

Indexed as

AnimalsExtracellular MatrixFibroblast Growth Factor 2GlycosaminoglycansHeparinoidsStem CellsFibroblast Growth Factor 2GlycosaminoglycansHeparinoids

Identifiers

PMID30668905
PMCPMC6860979
OpenAlexW2911704863

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.